Triple-negative breast cancer (TNBC) is an aggressive disease that makes up roughly 15% to 20% of breast cancer diagnoses. Standard chemotherapy works for about half of these patients. But there is a significant need for personalized options to improve outcomes for all patients.
Through the Breast Cancer Moon Shot®, MD Anderson is conducting an innovative clinical trial, called ARTEMIS, to develop personalized therapy approaches...
Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in...
A slice of RNA that doesn’t code for a protein manages to stifle tumor-suppressing genes and wreck the cellular mechanism that flags cancer...
Triple-negative breast cancer (TNBC) makes up 15 to 20 percent of breast cancer diagnoses. The condition often is considered a single disease, when in reality, TNBC is a catch-all diagnosis of biologically different breast cancer subtypes that lack expression of estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2 (HER2).
In patients with localized disease, a neoadjuvant chemotherapy...
Triple-negative breast cancer (TNBC) is an aggressive form of the disease that doesn’t rely on the hormones estrogen and progesterone or the...
Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone disease that accounts for one-fourth of all breast cancers, could...
When triple-negative breast cancer is still in its earliest, pre-cancerous stages, the tumor suppressor miRNA-29c becomes progressively deactivated...
In a pilot study conducted at MD Anderson Cancer Center, image-guided biopsies identified select breast cancer patients who achieved...
A new trial underway at MD Anderson may lead to new therapies for triple negative breast cancer.
Fifteen to 20% of breast cancers...
MD Anderson Cancer Center has been awarded $19.1 million in research grants in the most recent round of funding from the Cancer...